Perrigo Among Firms Requesting Delay In Conducting US Nitrosamine Risk Assessments
• By Joanne S. Eglovitch
After OTC and Rx drugs containing ranitidine and other ingredients were linked to nitrosamine, firms marketing drugs in the US have until 1 March to test for impurity risks from the potential carcinogenic associated with chemically synthesized APIs and all approved drugs that contain those APIs.
